Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

  • Kim, Gwi Eon (Department of Radiation Oncology, Jeju National University Hospital, Jeju National University School of Medicine) ;
  • Song, Hee-Sung (Department of Nuclear Medicine, Jeju National University Hospital, Jeju National University School of Medicine) ;
  • Ahn, Ki Jung (Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University of Medicine) ;
  • Kim, Young Suk (Department of Radiation Oncology, Jeju National University Hospital, Jeju National University School of Medicine)
  • Received : 2017.06.22
  • Accepted : 2017.08.16
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Sorafenib is widely used for unresectable and metastatic hepatocellular carcinomas. Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin that occurs after the administration of certain drugs. RRD after sorafenib treatment is rare; five cases have been reported thus far. We describe a 44-year-old man irradiated for chest wall bone metastasis from hepatocellular carcinoma. Eight days after radiotherapy completion, systemic therapy for metastatic hepatocellular carcinoma was initiated with sorafenib treatment. Eleven days after starting sorafenib, the patient complained of erythematous rash with pruritus in the chest wall, in a location consistent with the previous radiation field. Sorafenib was continued at the same dose, despite the RRD. The skin reaction subsided over the next 2 weeks without any medical intervention.

Keywords

References

  1. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45. https://doi.org/10.1016/S0167-8140(01)00328-0
  2. Stieb S, Riesterer O, Brussow C, Pestalozzi B, Guckenberger M, Weiler S. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature. Strahlenther Onkol 2016;192:342-8. https://doi.org/10.1007/s00066-016-0950-7
  3. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010;21:206-9. https://doi.org/10.1097/CAD.0b013e328333d679
  4. Robbins J, Wollner I, Ryu S. Sorafenib induced radiation recall dermatitis after spine radiosurgery. J Radiosurg SBRT 2011;1:71-4.
  5. Hsieh CH, Lin SC, Shueng PW, Kuo DY. Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy. Onco Targets Ther 2014;7:1111-4.
  6. Oh D, Park HC, Lim HY, Yoo BC. Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction. Radiat Oncol J 2013;31:171-4. https://doi.org/10.3857/roj.2013.31.3.171
  7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443
  8. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncol 1999;38:955-9. https://doi.org/10.1080/028418699432653
  9. Phillips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976;37(2 Suppl):1186-200. https://doi.org/10.1002/1097-0142(197602)37:2+<1186::AID-CNCR2820370830>3.0.CO;2-V
  10. Oanta A, Irimie M. Radiation recall dermatitis induced by tamoxifen. Bull Transilvania Univ Brasov VI Med Sci 2012;5:113-6.
  11. Hsieh CH, Jeng KS, Lin CC, et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009;29:65-71. https://doi.org/10.2165/0044011-200929010-00007
  12. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006;54:28-46. https://doi.org/10.1016/j.jaad.2005.08.054
  13. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.
  14. Ding X, Ji W, Li J, Zhang X, Wang L. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol 2011;6:24. https://doi.org/10.1186/1748-717X-6-24
  15. Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995;76:1069-72. https://doi.org/10.1002/1097-0142(19950915)76:6<1069::AID-CNCR2820760623>3.0.CO;2-7
  16. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400. https://doi.org/10.1016/S0360-3016(02)02773-6
  17. Levy A, Hollebecque A, Bourgier C, et al. Targeted therapyinduced radiation recall. Eur J Cancer 2013;49:1662-8. https://doi.org/10.1016/j.ejca.2012.12.009
  18. Ge J, Verma V, Hollander A, Langer C, Simone CB 2nd. Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review. J Thorac Dis 2016;8:E1589-E1593. https://doi.org/10.21037/jtd.2016.12.102
  19. Ubukata M, Kamio T, Ohchi T, Noguchi E, Tsukada H, Kameoka S. Radiation recall dermatitis occurring 6 years and 4 months after breast-conserving surgery: a case report. Oncol Lett 2016;11:3071-4. https://doi.org/10.3892/ol.2016.4346

Cited by

  1. Sorafenib/tenofovir : Radiation recall dermatitis: case report vol.1680, pp.1, 2017, https://doi.org/10.1007/s40278-017-39241-3
  2. Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma vol.19, pp.2, 2017, https://doi.org/10.17998/jlc.19.2.136
  3. Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report vol.12, pp.2, 2017, https://doi.org/10.2217/imt-2019-0020